vs
Side-by-side financial comparison of CS Disco, Inc. (LAW) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
CS Disco, Inc. is the larger business by last-quarter revenue ($41.9M vs $23.0M, roughly 1.8× Intellia Therapeutics, Inc.). CS Disco, Inc. runs the higher net margin — -23.0% vs -416.2%, a 393.2% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 14.3%). Over the past eight quarters, CS Disco, Inc.'s revenue compounded faster (7.9% CAGR vs -10.8%).
CS Disco, Inc. is a leading legal technology provider that develops cloud-based software solutions for legal practitioners. Its core offerings include e-discovery, document review, case management, and legal workflow automation tools, serving law firms, corporate legal teams, and government legal departments primarily in North America.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
LAW vs NTLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.9M | $23.0M |
| Net Profit | $-9.6M | $-95.8M |
| Gross Margin | 74.2% | — |
| Operating Margin | 1.7% | -428.9% |
| Net Margin | -23.0% | -416.2% |
| Revenue YoY | 14.3% | 78.8% |
| Net Profit YoY | 15.6% | 25.7% |
| EPS (diluted) | $-0.15 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $41.9M | — | ||
| Q4 25 | $41.2M | $23.0M | ||
| Q3 25 | $40.9M | $13.8M | ||
| Q2 25 | $38.1M | $14.2M | ||
| Q1 25 | $36.7M | $16.6M | ||
| Q4 24 | $37.0M | $12.9M | ||
| Q3 24 | $36.3M | $9.1M | ||
| Q2 24 | $36.0M | $7.0M |
| Q1 26 | $-9.6M | — | ||
| Q4 25 | $-8.5M | $-95.8M | ||
| Q3 25 | $-13.7M | $-101.3M | ||
| Q2 25 | $-10.8M | $-101.3M | ||
| Q1 25 | $-11.4M | $-114.3M | ||
| Q4 24 | $-25.2M | $-128.9M | ||
| Q3 24 | $-9.2M | $-135.7M | ||
| Q2 24 | $-10.8M | $-147.0M |
| Q1 26 | 74.2% | — | ||
| Q4 25 | 75.1% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 74.6% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 74.2% | — | ||
| Q3 24 | 73.1% | — | ||
| Q2 24 | 74.2% | — |
| Q1 26 | 1.7% | — | ||
| Q4 25 | -22.4% | -428.9% | ||
| Q3 25 | -35.3% | -808.9% | ||
| Q2 25 | -31.0% | -772.2% | ||
| Q1 25 | -34.4% | -726.6% | ||
| Q4 24 | -70.6% | -1059.9% | ||
| Q3 24 | -30.0% | -1589.0% | ||
| Q2 24 | -34.4% | -1998.6% |
| Q1 26 | -23.0% | — | ||
| Q4 25 | -20.7% | -416.2% | ||
| Q3 25 | -33.4% | -735.2% | ||
| Q2 25 | -28.4% | -710.8% | ||
| Q1 25 | -31.1% | -687.6% | ||
| Q4 24 | -68.1% | -1001.2% | ||
| Q3 24 | -25.3% | -1489.5% | ||
| Q2 24 | -30.1% | -2112.6% |
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.13 | $-0.81 | ||
| Q3 25 | $-0.22 | $-0.92 | ||
| Q2 25 | $-0.18 | $-0.98 | ||
| Q1 25 | $-0.19 | $-1.10 | ||
| Q4 24 | $-0.43 | $-1.27 | ||
| Q3 24 | $-0.15 | $-1.34 | ||
| Q2 24 | $-0.18 | $-1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $123.9M | $671.4M |
| Total Assets | $162.4M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $103.0M | — | ||
| Q4 25 | $114.6M | $449.9M | ||
| Q3 25 | $113.5M | $511.0M | ||
| Q2 25 | $114.5M | $459.7M | ||
| Q1 25 | $118.8M | $503.7M | ||
| Q4 24 | $129.1M | $601.5M | ||
| Q3 24 | $126.8M | $658.1M | ||
| Q2 24 | $130.0M | $691.1M |
| Q1 26 | $123.9M | — | ||
| Q4 25 | $128.1M | $671.4M | ||
| Q3 25 | $130.6M | $748.4M | ||
| Q2 25 | $137.9M | $715.3M | ||
| Q1 25 | $142.2M | $779.9M | ||
| Q4 24 | $147.5M | $872.0M | ||
| Q3 24 | $167.3M | $962.6M | ||
| Q2 24 | $170.9M | $971.1M |
| Q1 26 | $162.4M | — | ||
| Q4 25 | $173.6M | $842.1M | ||
| Q3 25 | $174.8M | $925.3M | ||
| Q2 25 | $164.9M | $898.9M | ||
| Q1 25 | $168.0M | $986.2M | ||
| Q4 24 | $180.3M | $1.2B | ||
| Q3 24 | $194.4M | $1.2B | ||
| Q2 24 | $198.0M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-11.7M | — | ||
| Q4 25 | $762.0K | $-69.3M | ||
| Q3 25 | $-979.0K | $-76.9M | ||
| Q2 25 | $-4.2M | $-99.6M | ||
| Q1 25 | $-10.5M | $-148.9M | ||
| Q4 24 | $2.1M | $-85.2M | ||
| Q3 24 | $-2.9M | $-84.8M | ||
| Q2 24 | $-650.0K | $-58.2M |
| Q1 26 | — | — | ||
| Q4 25 | $255.0K | $-69.4M | ||
| Q3 25 | $-2.0M | $-76.9M | ||
| Q2 25 | $-5.2M | $-99.9M | ||
| Q1 25 | $-11.0M | $-149.7M | ||
| Q4 24 | $1.5M | $-86.2M | ||
| Q3 24 | $-3.7M | $-86.1M | ||
| Q2 24 | $-1.3M | $-59.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | -301.6% | ||
| Q3 25 | -5.0% | -558.2% | ||
| Q2 25 | -13.6% | -701.0% | ||
| Q1 25 | -30.1% | -900.1% | ||
| Q4 24 | 4.1% | -669.4% | ||
| Q3 24 | -10.3% | -945.2% | ||
| Q2 24 | -3.6% | -850.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 0.5% | ||
| Q3 25 | 2.6% | 0.2% | ||
| Q2 25 | 2.5% | 1.7% | ||
| Q1 25 | 1.4% | 4.4% | ||
| Q4 24 | 1.5% | 7.6% | ||
| Q3 24 | 2.4% | 14.0% | ||
| Q2 24 | 1.8% | 14.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LAW
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
